Clearing the Air on Residual Solvents - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Clearing the Air on Residual Solvents
USP 9467: Residual Solvents will take effect on July 1, 2008. But does the industry understand these specifications—and is it prepared?

Pharmaceutical Technology

Figure 1: Identifying residual solvents and testing procedures.
There are regulatory differences, however, between USP ‹467› and ICH Q3C. ICH Q3C is a guideline, which means it is not enforceable. Currently, it applies to new drug applications (NDAs) and abbreviated new drug applications (ANDAs) approved after 1997 and applications that reference it. USP ‹467› is a mandatory drug standard according to the Food, Drug, and Cosmetic Act of 1938. It applies to all compendial drug products; that is, products with a USP monograph.

"There are a lot of drug products that are approved by the agency that do not have a USP monograph, but the NDA and ANDA are still reviewed by the agency and even though there is no requirement in USP necessarily for residual solvents, we always review all drug applications to make sure residual solvents are tested for, and ICH Q3C guidance is still fully applicable to those drug products that perhaps do not have a monograph in USP," says Ouderkirk.

USP ‹467› and ICH Q3C categorize residual solvents, including those previously under the OVI chapter, into three classes according to their toxicity level (see sidebar, "Residual solvents classifications"). Both documents assess the risk to human health according to permitted daily exposure (PDE), which differs from the terminology used by the International Program on Chemical Safety (which uses "tolerable daily intake") and the World Health Organization (which uses "acceptable daily intake"). Both documents also list concentration limits (in ppm) for Class 1 residual solvents and limits (in ppm concentration and PDE) for Class 2 residual solvents. Questions about these limits, including how they are calculated and where they apply, are widespread.

Clarification on limits

Understanding the difference between the limits in terms of PDE and the limits in terms of concentration (in ppm) has turned out to be one of the most crucial areas of understanding USP ‹467›. Those who have followed the evolution of the general chapter are quick to urge readers to read the text very carefully.

Residual solvents classifications*
The text states that the chapter applies to existing drug substances, excipients, and products, and that all substances and products are subject to relevant control of solvents likely to be present in a substance or product. As Delwyn Schumacher, principal chemist in the Methods Development Department at Lancaster Laboratories (Lancaster, PA), observes, "that statement pretty much means that if a solvent is used in a drug-related manufacturing process, it [the solvent] needs to be evaluated one way or another in the produced material for compliance with the applicable limits."

One key point that industry experts, regulatory agencies, and ingredient suppliers are making, however, is that the limits specified in ‹467›, including those listed for Class 2 residual solvents, apply only to the finished drug product. The current misinterpretation is that these limits apply to the individual ingredients of the drug product.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here